GLP-1 + Wellbutrin (Bupropion): The Stacking Evidence

Wellbutrin (bupropion) is the antidepressant most often picked when weight gain is a concern, and it is also the bupropion half of Contrave — an FDA-approved obesity medication that combines bupropion 360 mg with naltrexone 32 mg. Patients on semaglutide or tirzepatide who also take bupropion are common, but the combination has never been formally trialed. This article walks through what the published evidence does say: bupropion’s standalone weight effect (Anderson 2002^[1]), the four COR trials that built Contrave (Greenway 2010^[2], Apovian 2013^[3], Hollander 2013^[4], Wadden 2011^[5]), the LIGHT cardiovascular outcomes trial (Nissen 2016^[6]), the smoking-cessation overlap (Hurt 1997^[8]), and the seizure-threshold ceiling that constrains how high bupropion can be dosed alongside a GLP-1.

The honest summary

• Bupropion alone is weight-favorable, modestly. Anderson 2002^[1] (48-week placebo-controlled trial of bupropion SR 300 and 400 mg/day in obese adults without depression) found mean placebo-subtracted weight loss of roughly 2–4 kg, dose-dependent. The Endocrine Society 2015 guideline (Apovian^[9]) categorizes bupropion as a “weight-favorable antidepressant” alongside the orphan label fluoxetine has at high dose.
• Contrave (bupropion 360 mg + naltrexone 32 mg) roughly doubles the bupropion-alone effect. Across the four COR trials, completers averaged about −6% body weight at 56 weeks vs −1% on placebo (Greenway 2010^[2], Apovian 2013^[3], Hollander 2013^[4], Wadden 2011^[5]). That is meaningfully below GLP-1 results (sema 2.4 mg ~15%, tirzepatide 15 mg ~21%) but real.
• The cardiovascular safety signal is reassuring but incomplete. The LIGHT trial (Nissen 2016, JAMA^[6]) was terminated early after a data leak; the interim analysis did not show MACE excess, but the trial was underpowered for a definitive non-inferiority conclusion.
• Seizure threshold is the hard ceiling. Bupropion seizure incidence climbs above 0.4% at total daily doses above 450 mg (Jefferson 2005^[11]). Eating disorder history (bulimia, anorexia nervosa) and abrupt alcohol or benzodiazepine withdrawal are absolute contraindications regardless of dose.
• Stacking GLP-1 + bupropion is unstudied but mechanistically reasonable. The two drugs hit parallel pathways — GLP-1 receptors in the hypothalamus and brainstem, bupropion via norepinephrine / dopamine reuptake and POMC neuron activation (Greenway 2009^[7]). Real-world clinicians do combine them. No RCT has tested the additive effect.

What bupropion does on its own: the weight evidence

Bupropion was first approved in 1985 for major depression, then reformulated as sustained-release (Wellbutrin SR) and extended- release (Wellbutrin XL). A separate brand, Zyban, holds the smoking-cessation indication. The molecule is a norepinephrine and dopamine reuptake inhibitor with no direct serotonergic activity, which is why it does not produce the weight gain or sexual side effects characteristic of SSRIs.

Anderson 2002^[1] was the pivotal 48-week placebo- controlled trial that established bupropion’s standalone weight effect. 327 obese non-depressed adults were randomized to bupropion SR 300 mg/day, bupropion SR 400 mg/day, or placebo, alongside a 1,600 kcal/day diet. Completer-analysis mean weight loss at week 48 was −7.2% on 400 mg, −6.2% on 300 mg, and −3.2% on placebo. The placebo-subtracted effect (~3–4 kg) is real but smaller than any modern GLP-1.

The Endocrine Society 2015 pharmacological management of obesity guideline (Apovian^[9]) recommends bupropion preferentially over other antidepressants when a patient with obesity needs antidepressant therapy. The guideline does not endorse bupropion monotherapy for obesity in non-depressed patients — the effect size is too small for standalone FDA approval — but it is the preferred antidepressant in the comorbid case.

The Contrave story: COR-I through COR-BMOD

Contrave (naltrexone SR 32 mg + bupropion SR 360 mg) was FDA- approved in 2014 on the strength of four phase 3 trials collectively called the COR program. The rationale was Greenway 2009^[7]: bupropion stimulates POMC neurons in the hypothalamus (releasing alpha-MSH, an anorexigenic peptide), but those same neurons co-release beta-endorphin, which feeds back through mu-opioid receptors to slow further POMC firing. Naltrexone blocks that feedback, allowing bupropion’s POMC stimulation to be sustained. It is the only FDA-approved obesity drug built on an explicit mu-opioid-receptor-block mechanism.

COR-I (Greenway 2010, Lancet^[2]) randomized 1,742 adults with obesity to naltrexone SR / bupropion SR (NB) 16 mg/360 mg, NB 32 mg/360 mg, or placebo for 56 weeks. Mean weight loss in completers was −6.1% on NB32 vs −1.3% on placebo. COR-II (Apovian 2013^[3]) ran NB 32/360 vs placebo in 1,496 obese adults and produced −6.4% vs −1.2%. COR-Diabetes (Hollander 2013^[4]) ran NB 32/360 in overweight / obese adults with type 2 diabetes and found −5.0% vs −1.8%, plus a 0.6 percentage-point HbA1c improvement. COR-BMOD (Wadden 2011^[5]) ran NB 32/360 plus intensive behavior modification in 793 adults and produced −9.3% vs −5.1% on placebo plus the same behavior modification.

The aggregate signal: Contrave produces about −5 to −6% placebo-subtracted weight loss at one year. That is a meaningful improvement over bupropion alone (placebo- subtracted ~3–4%) but well below semaglutide 2.4 mg (~12% placebo-subtracted) or tirzepatide 15 mg (~17% placebo- subtracted). For patients who cannot tolerate or access a GLP-1, Contrave is a credible alternative; for patients who can use a GLP-1, it is rarely first-line.

The LIGHT trial: cardiovascular safety, sort of

Nissen 2016 (JAMA^[6]) reported the LIGHT trial, a prospective MACE-outcomes RCT of Contrave vs placebo in 8,910 overweight or obese adults with cardiovascular risk factors. The trial was terminated early after sponsor-driven interim analyses leaked. At 50% information accrual, the MACE hazard ratio was 0.88 (95% CI 0.57–1.34), consistent with no excess risk. The early termination left the trial underpowered for a definitive non-inferiority claim, so the FDA-mandated cardiovascular outcomes question remains formally unresolved. In practice, the Endocrine Society guideline^[9] and FDA labeling treat Contrave as cardiovascularly neutral, not as cardioprotective — a meaningful contrast with semaglutide (SELECT) and dulaglutide (REWIND), both of which carry primary cardiovascular outcomes labels.

Smoking cessation: the overlap that makes Wellbutrin useful

Hurt 1997 (NEJM^[8]) is the pivotal smoking-cessation trial that supported the Zyban label: sustained-release bupropion 300 mg/day roughly doubled 1-year smoking-cessation rates vs placebo (23% vs 12%). Crucially, the bupropion arm also gained meaningfully less weight than the placebo arm after quitting — an average of about 1.5 kg less — which matters because the typical quit-smoking weight gain of 5 kg / 10 lb is one of the most common reasons smokers cite for not attempting cessation.

For a patient who smokes, has obesity, and wants a GLP-1: the order of operations is usually GLP-1 first (the larger effect) plus bupropion 300 mg XL for cessation, with the bupropion carrying the additional benefit of blocking quit-related weight gain. The combination is unstudied as a trio but well-tolerated in practice.

The seizure-threshold constraint

Bupropion’s seizure risk is dose-dependent. Jefferson 2005^[11] reviewed the pharmacokinetic and formulation literature and reported seizure incidence of approximately 0.1% at total daily doses of 300 mg or less (immediate-release regimens divided three times daily, or sustained / extended release once or twice daily), climbing to roughly 0.4% at 450 mg/day. The 450 mg/day ceiling is hard: above it, seizure risk rises steeply and the FDA labeling reflects that.

Eating disorder history is an absolute contraindication. Active bulimia or anorexia nervosa is associated with electrolyte derangements and metabolic instability that compound seizure risk. Abrupt alcohol or benzodiazepine withdrawal is also a contraindication for the same reason.

There is no published evidence that GLP-1 agonists lower the seizure threshold. The conservative stacking recommendation is therefore straightforward: keep total bupropion below 450 mg/day, screen for and document the absence of eating-disorder history before initiation, and do not co-prescribe with other threshold-lowering agents (tramadol, theophylline, high-dose tricyclics) when avoidable.

The GLP-1 + bupropion combination: what we know and do not

No randomized trial has tested semaglutide or tirzepatide combined with bupropion. The mechanistic case for additivity is reasonable: GLP-1 agonists act at hypothalamic and brainstem GLP-1 receptors plus a vagal afferent loop; bupropion acts via norepinephrine and dopamine reuptake plus POMC neuron stimulation. The pathways are independent, so additive but not synergistic effects are plausible.

Pharmacokinetically, bupropion is a CYP2B6 substrate and a CYP2D6 inhibitor; neither pathway is meaningfully shared with the small-molecule oral metabolism of GLP-1 agonists (the injectables are peptides and bypass hepatic CYP entirely). The gastric-emptying delay produced by semaglutide and tirzepatide can shift the absorption Cmax of orally administered bupropion modestly later, but total AUC is preserved. There is no published dose adjustment recommendation; the standard 300 mg XL once-daily regimen is usually maintained.

Bupropion mildly elevates resting blood pressure (mean increase ~3–5 mm Hg systolic) and heart rate; GLP-1 agonists modestly decrease both. The directional offset is favorable. A baseline blood-pressure check plus a follow-up at the bupropion 4-week mark is reasonable and consistent with the FDA labels for both classes.

The relevant adjacent evidence is the Hendershot 2025 JAMA Psychiatry RCT (semaglutide for alcohol use disorder^[10]), which demonstrated that semaglutide 2.4 mg reduced average drinks per drinking day by approximately a half-drink over 9 weeks. Bupropion has a small (and somewhat contested) AUD signal of its own. Patients who carry comorbid AUD and obesity are a population for whom the dual-pathway argument for combination is at its strongest, even though no head-to-head trial has tested the combination.

Magnitude: where each option sits at 56–68 weeks

Practical guidance for stacking

1. Bupropion XL 300 mg once daily is the standard dose when paired with a GLP-1. Going to 450 mg/day is acceptable for treatment-resistant depression but increases seizure risk; we would not push past 300 mg solely to chase additional weight effect.
2. Screen for eating-disorder history before initiation. Document a no-history response in the chart. Bulimia or anorexia nervosa, current or remote, is an absolute contraindication.
3. Baseline and 4-week blood pressure. Bupropion adds ~3–5 mm Hg systolic; the GLP-1 typically subtracts a similar amount. Net is usually neutral but should be documented.
4. Smoking cessation is a strong adjunct indication. A patient on a GLP-1 who smokes is a near-ideal candidate for adding bupropion XL 300 mg, with the bupropion serving dual purpose: cessation aid and offset of quit-related weight gain (Hurt 1997^[8]).
5. Already on Contrave? Discontinue before adding a GLP-1. Stacking Contrave (which already contains bupropion 360 mg plus naltrexone 32 mg) on top of a GLP-1 is unstudied. The naltrexone half blocks endogenous opioid tone, which is mechanistically irrelevant to GLP-1 weight effect but adds GI and mood side-effect burden. Transition to GLP-1 monotherapy, then add separate bupropion 300 mg XL if a mood / smoking / weight-favorable antidepressant is still indicated.
6. Telehealth fulfillment. Hims, Brightside, and Cerebral all prescribe bupropion; GLP-1 prescriptions typically come from a separate weight-loss telehealth (Found, Ro, Sequence) or in-person clinic. Two prescribers is the common configuration; both should be aware of the combination.

When NOT to use this combination

• Active or remote eating disorder. Absolute contraindication for bupropion regardless of dose.
• Seizure disorder history. Bupropion lowers the seizure threshold; alternative antidepressants (mirtazapine is weight-positive but seizure-neutral; vortioxetine is weight-neutral and seizure-neutral) are preferred.
• Uncontrolled hypertension. Add the ~3–5 mm Hg systolic bupropion bump to baseline BP; if baseline is already > 140/90, treat hypertension first.
• Concurrent MAOI within 14 days. Absolute contraindication.
• Opioid dependence. Not a contraindication to bupropion alone, but Contrave (which contains naltrexone) would precipitate withdrawal. For patients on chronic opioids, bupropion-monotherapy plus GLP-1 is the safer pairing than Contrave plus GLP-1.

Related research and tools

• GLP-1 + SSRI (Lexapro, Zoloft, Prozac) interaction evidence — how the weight-favorable bupropion compares with serotonergic antidepressants in GLP-1 patients
• GLP-1 + ADHD stimulants (Adderall, Vyvanse) evidence — the other dopaminergic-axis combination that comes up alongside bupropion
• GLP-1 brain fog and cognitive effects — bupropion is often added to address the activating cognitive profile patients want
• Wellbutrin XL weight loss evidence — the bupropion-monotherapy weight effect in detail
• Naltrexone and Contrave weight loss evidence — the naltrexone half of the Contrave combination
• Antidepressants and weight on a GLP-1 — the broader picture of antidepressant choice for GLP-1 patients
• Contrave on Weight Loss Rankings — the drug profile, pricing, and side-effect summary

Important disclaimer. This article is educational and does not constitute medical advice. Bupropion carries dose-dependent seizure risk and is contraindicated in patients with eating disorder history, seizure disorder, MAOI use within 14 days, or abrupt alcohol or benzodiazepine withdrawal. The combination of bupropion with semaglutide or tirzepatide has not been formally trialed; the mechanistic rationale is reasonable but additive weight outcomes are projected, not measured. Discuss any combination prescribing with your prescribing clinician. PMIDs were verified live against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if a prospective RCT of GLP-1 plus bupropion is published, or if the FDA labels for Contrave or Wellbutrin change materially.